Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction.
Anghelescu
I
I
Klawe
C
C
Himmerich
H
H
Szegedi
A
A
D000379:Agoraphobia / Q000523:psychology; D000437:Alcoholism / Q000523:psychology; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000150:complications* / Q000188:drug therapy; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006212:Hallucinations / Q000139:chemically induced*; D006801:Humans; D020762:Infarction, Posterior Cerebral Artery / Q000150:complications* / Q000523:psychology; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000077236:Topiramate; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D005632:Fructose; D018696:Neuroprotective Agents; D017367:Selective Serotonin Reuptake Inhibitors; D000077236:Topiramate; D000069470:Venlafaxine Hydrochloride